Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of Biologics and Oral Treatments for Plaque Psoriasis
April W. Armstrong, L. Puig, Avani Joshi, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 3, pp. 258-258
Open Access | Times Cited: 215

Showing 1-25 of 215 citing articles:

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
April W. Armstrong, Charlotte Read
JAMA (2020) Vol. 323, Iss. 19, pp. 1945-1945
Closed Access | Times Cited: 1519
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, et al.
The Lancet (2021) Vol. 397, Iss. 10275, pp. 754-766
Closed Access | Times Cited: 404
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2021) Vol. 2021, Iss. 12
Open Access | Times Cited: 134
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, I. García‐Doval, et al.
Cochrane library (2022) Vol. 2022, Iss. 8
Open Access | Times Cited: 106
Challenges and Future Trends in the Treatment of Psoriasis
Hyun Ji Lee, Miri Kim
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13313-13313
Open Access | Times Cited: 106
Disease modification in inflammatory skin disorders: opportunities and challenges
Thomas Bieber
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 662-680
Closed Access | Times Cited: 43
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
Robert Bissonnette, Andreas Pinter, Laura K. Ferris, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 6, pp. 510-521
Closed Access | Times Cited: 29
Emerging roles of SIRT1 activator, SRT2104, in disease treatment
Ning Chang, Junyang Li, Sufen Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Role of phototherapy in the era of biologics
Angeli Eloise Torres, Alexis B. Lyons, Iltefat Hamzavi, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 2, pp. 479-485
Open Access | Times Cited: 74
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 885-905
Open Access | Times Cited: 62
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Hakim Ben Abdallah, Claus Johansen, Lars Iversen
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 83-97
Open Access | Times Cited: 58
Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects
Ummu Umaimah Mohd Nordin, Noraini Ahmad, Norazlinaliza Salim, et al.
RSC Advances (2021) Vol. 11, Iss. 46, pp. 29080-29101
Open Access | Times Cited: 57
From Empirical to Pathogenesis-Based Treatments for Psoriasis
P.C.M. van de Kerkhof
Journal of Investigative Dermatology (2022) Vol. 142, Iss. 7, pp. 1778-1785
Open Access | Times Cited: 54
Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 7
Open Access | Times Cited: 50
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
Iain B. McInnes, L. Sawyer, Kristen Markus, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002074-e002074
Open Access | Times Cited: 48
Biologics‐Loaded Photothermally Dissolvable Hyaluronic Acid Microneedle Patch for Psoriasis Treatment
Dan Wu, Xin Shou, Yunru Yu, et al.
Advanced Functional Materials (2022) Vol. 32, Iss. 47
Closed Access | Times Cited: 47
Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art review
B.H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Umme Hani, et al.
International Journal of Pharmaceutics (2023) Vol. 632, pp. 122591-122591
Closed Access | Times Cited: 38
Biologics for Psoriasis
A. Mitchel Wride, Gloria F. Chen, Sarah L. Spaulding, et al.
Dermatologic Clinics (2024) Vol. 42, Iss. 3, pp. 339-355
Closed Access | Times Cited: 15
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Neil H. Shear, Keith A. Betts, Ahmed M. Soliman, et al.
Journal of the American Academy of Dermatology (2021) Vol. 85, Iss. 3, pp. 572-581
Open Access | Times Cited: 50
The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis
G. Fragoulis, Stefan Siebert
Musculoskeletal Care (2022) Vol. 20, Iss. S1
Open Access | Times Cited: 28
Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation
Hakim Ben Abdallah, Sabine Seeler, Anne Bregnhøj, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Richard B. Warren, Yichen Zhong, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2839-2857
Open Access | Times Cited: 19
Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis
Alexander C. Egilman, Aaron S. Kesselheim, Jerry Avorn, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 4, pp. 409-409
Closed Access | Times Cited: 7
Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis
Stefano G. Daniele, Sherif A. Eldirany, Giovanni Damiani, et al.
JID Innovations (2024) Vol. 4, Iss. 2, pp. 100261-100261
Open Access | Times Cited: 6
Actualización práctica de las recomendaciones del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología (GPS) para el tratamiento de la psoriasis con terapia biológica. Parte 1. «Conceptos y manejo general de la psoriasis con terapia biológica»
J.M. Carrascosa, L. Puig, I. Belinchón, et al.
Actas Dermo-Sifiliográficas (2021) Vol. 113, Iss. 3, pp. 261-277
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top